From: BCL2L12 is a Novel Biomarker for the Prediction of Short-Term Relapse in Nasopharyngeal Carcinoma
 |  | Number of patients (%) |  | |
---|---|---|---|---|
 | Total | BCL2L12-negative | BCL2L12-positive | P |
Cases | 79 | 37 (46.8) | 42 (53.2) | Â |
Sex | Â | Â | Â | Â |
Male | 51 | 19 (37.3) | 32 (62.7) | 0.033b |
Female | 28 | 18 (64.3) | 10 (35.7) | Â |
Age (years) | Â | Â | Â | Â |
≤30 | 25 | 11 (44.0) | 14 (56.0) | 0.81b |
>30 | 54 | 26 (48.1) | 28 (51.9) | Â |
Tumor histologyc | Â | Â | Â | Â |
Undifferentiated | 40 | 23 (57.5) | 17 (42.5) | 0.045b |
Nonkeratinizing | 38 | 13 (34.2) | 25 (65.8) | Â |
Unknown | 1 | Â | Â | Â |
Tumor extentd | Â | Â | Â | Â |
T1/T2 | 28 | 17 (60.7) | 11 (39.3) | 0.099b |
T3/T4 | 51 | 20 (39.2) | 31 (60.8) | Â |
Regional lymph node status | Â | Â | Â | Â |
N0 | 7 | 6 (85.7) | 1 (14.3) | 0.17e |
N1 | 12 | 6 (50.0) | 6 (50.0) | Â |
N2 | 28 | 12 (42.9) | 16 (57.1) | Â |
N3 | 32 | 13 (40.6) | 19 (59.4) | Â |
Distant metastasis | Â | Â | Â | Â |
M0 | 55 | 31 (56.4) | 24 (43.6) | 0.014b |
M1 | 24 | 6 (25.0) | 18 (75.0) | Â |